Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 16, 2011

Teva to Acquire Majority Stake in Japanese Generics Firm Taiyo for $460M

Teva to Acquire Majority Stake in Japanese Generics Firm Taiyo for $460M

Israeli firm is looking to acquire Taiyo outright and expects to achieve $1B in Japanese generics sales before 2015.[Vladislav Gajic - Fotolia.com]

  • Teva Pharmaceutical Industries is paying $460 million for a 57% stake in privately held Japanese generics firm Taiyo Pharmaceutical Industry, and is looking to purchase Taiyo outright, in a deal that values the latter at $1.3 billion.

    Teva claims Taiyo is the third largest generics firm in Japan, with sales of $530 million in 2010, two manufacturing facilities, and strong R&D and regulatory expertise. Its portfolio includes over 550 generic drugs spanning a broad range of therapeutic areas and dosage forms. “Taiyo’s strong market reach, cutting-edge production facilities, and impressively large product portfolio, combined with Teva’s scale and capabilities as the world’s largest generics company, will enable us to offer a much wider range of high-quality, affordable generics to a much larger section of the Japanese market,” comments Shlomo Yanai, Teva president and CEO. Teva further predicts the acquisition will allow it to reach its 2015 target of $1 billion in sales in Japan ahead of schedule.

    The firm says Japan is the second largest pharmaceutical market in the world, valued at $96 billion in 2010. Although there is currently a relatively low, 23% rate of generic penetration, the Japanese government is making moves to increase this to 30% by 2012, Teva adds.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »